Currently, the majority of ovarian cancers – upwards of 75 percent – are of the subtype “high grade serous carcinoma,” which is the type being treated in this phase 2 study. While most patients with this malignant ovarian cancer subtype initially respond to standard cytotoxic therapies, more than 80 percent will relapse and succumb to the disease within five years. New treatments are urgently needed for this deadliest of gynecological cancers, which is diagnosed in more than a quarter-million women worldwide each year according to World Health Organization estimates.